免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT). (HIC-CAT)

Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT). (HIC-CAT)

Study Description
Brief Summary:
A population-based registry in Catalonia of patients with acute spontaneous Intracerebral Hemorrhage, to investigate whether type of center and time from onset to admission is associated with functional outcome and mortality.

Condition or disease Intervention/treatment
Intracerebral Hemorrhage Other: Type of center

Detailed Description:

Introduction. Recent studies show that there are potentially beneficial therapeutic measures for the patient with acute intracerebral hemorrhage (ICH), which should be applied urgently and that some would only be available in tertiary stroke centers (TSC). However, the transportation criteria for ICH patients are not well defined.

Objectives: Design and implementation of a registry (HIC-CAT) of patients with HIC in the healthcare network of public hospitals in Catalonia, which does not modify the current logistics but collects data related to patients and TSC, interhospital transfers and non-TSC centers. The registry will allow us to evaluate the hypothesis that: 1) Patient care in TSC decreases the probability of death or dependence in patients with spontaneous ICH compared to non-TSC; and 2) The shorter the time until admission to a TSC, the better the survival and functional outcome. This will be due to the application of diagnostic, therapeutic and structural measures at the TSC. In addition, organ donation will be more frequent in a TSC.

Methods: Observational, prospective, multicentre, population study of 2500 consecutive patients with spontaneous ICH of less than 24 hours from the onset of symptoms and Rankin scale score 0-3. We will collect times, clinical and radiological variables, vital and functional outcome at 3 months follow-up. Number of organ donations. Primary variable: Functional outcome at 3 months (Rankin 0-3). Statistics: Multivariate analysis with logistic regression, propensity matching scores.

Study Design
Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Months
Official Title: Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : December 2021
Arms and Interventions
Outcome Measures
Primary Outcome Measures :
  1. Functional outcome [ Time Frame: 3 months after onset ]
    Rankin scale score, favourable if 0,1, 2 or 3


Secondary Outcome Measures :
  1. Mortality [ Time Frame: 3 months ]
    mortality within the first 3 months after onset

  2. Hematoma expansion [ Time Frame: 72 hours ]
    increase in hematoma volume (>33% and/or 6 ml) from baseline CT to follow-up CT

  3. Stroke Unit admission [ Time Frame: 3 months ]
    Percentage of patients admitted to a stroke unit

  4. Neurological worsening [ Time Frame: During admission ]
    increase in 4 or more points in the NIHSS score and/or decrease >1 point in the Glasgow coma scale score


Eligibility Criteria
Contacts and Locations
Tracking Information
First Submitted Date May 16, 2019
First Posted Date May 20, 2019
Last Update Posted Date May 20, 2019
Estimated Study Start Date September 2019
Estimated Primary Completion Date September 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 16, 2019)
Functional outcome [ Time Frame: 3 months after onset ]
Rankin scale score, favourable if 0,1, 2 or 3
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: May 16, 2019)
  • Mortality [ Time Frame: 3 months ]
    mortality within the first 3 months after onset
  • Hematoma expansion [ Time Frame: 72 hours ]
    increase in hematoma volume (>33% and/or 6 ml) from baseline CT to follow-up CT
  • Stroke Unit admission [ Time Frame: 3 months ]
    Percentage of patients admitted to a stroke unit
  • Neurological worsening [ Time Frame: During admission ]
    increase in 4 or more points in the NIHSS score and/or decrease >1 point in the Glasgow coma scale score
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
Official Title Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia
Brief Summary A population-based registry in Catalonia of patients with acute spontaneous Intracerebral Hemorrhage, to investigate whether type of center and time from onset to admission is associated with functional outcome and mortality.
Detailed Description

Introduction. Recent studies show that there are potentially beneficial therapeutic measures for the patient with acute intracerebral hemorrhage (ICH), which should be applied urgently and that some would only be available in tertiary stroke centers (TSC). However, the transportation criteria for ICH patients are not well defined.

Objectives: Design and implementation of a registry (HIC-CAT) of patients with HIC in the healthcare network of public hospitals in Catalonia, which does not modify the current logistics but collects data related to patients and TSC, interhospital transfers and non-TSC centers. The registry will allow us to evaluate the hypothesis that: 1) Patient care in TSC decreases the probability of death or dependence in patients with spontaneous ICH compared to non-TSC; and 2) The shorter the time until admission to a TSC, the better the survival and functional outcome. This will be due to the application of diagnostic, therapeutic and structural measures at the TSC. In addition, organ donation will be more frequent in a TSC.

Methods: Observational, prospective, multicentre, population study of 2500 consecutive patients with spontaneous ICH of less than 24 hours from the onset of symptoms and Rankin scale score 0-3. We will collect times, clinical and radiological variables, vital and functional outcome at 3 months follow-up. Number of organ donations. Primary variable: Functional outcome at 3 months (Rankin 0-3). Statistics: Multivariate analysis with logistic regression, propensity matching scores.

Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 3 Months
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population All patients with a diagnosis of acute spontaneous intracerebral hemorrhage in Catalonia during a period of 2 years
Condition Intracerebral Hemorrhage
Intervention Other: Type of center
Tertiary versus non-tertiary
Other Name: Time from onset to admission
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: May 16, 2019)
2500
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 2021
Estimated Primary Completion Date September 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patient with a diagnosis of spontaneous intracerebral hemorrhage who is diagnosed in any of the participant hospitals

Exclusion Criteria:

  • Traumatic intracerebral hemorrhage
  • >24 hours from onset to admission
  • Prior Rankin scale score >3
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Joan Martí-Fàbregas, MD,PhD +34935565986 jmarti@santpau.cat
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT03956485
Other Study ID Numbers IIBSP-HIC-2019-22
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study Sponsor Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
  • Fundació Ictus
  • Pla Director de la Malaltia vascular Cerebral, Departament de Salut
Investigators Not Provided
PRS Account Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Verification Date May 2019